![Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience - Annals of Oncology Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/df9e6493-efdb-4103-887c-1db984d3ce36/gr1.jpg)
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience - Annals of Oncology
![Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials](https://mma.prnewswire.com/media/1315965/MD_Anderson_Cancer_Center_Logo.jpg)
Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials
![The MD Anderson Cancer Center in Madrid inaugurates one of the largest Phase I Clinical Trials units in Europe - Distefar del Sur SL The MD Anderson Cancer Center in Madrid inaugurates one of the largest Phase I Clinical Trials units in Europe - Distefar del Sur SL](https://distefar.com/dist/wp-content/uploads/2021/11/immedicohospitalario_anderson_cancer_26358_03131341-750x480.png)